Abstract
Background: Sibutramine is a drug that is used in the treatment of obesity. There are currently no epidemiological studies relating to sibutramine exposure in pregnancy. The objective of our study was to determine whether sibutramine exposure during pregnancy constitutes a risk factor to the mother and developing fetus.
Methods: Fifty-two pregnant women who were exposed to sibutramine in the first trimester of pregnancy, when they were unaware of being pregnant, contacted our Teratology Information Service. We recorded the prospective outcomes of this case series between May 2001 and September 2004 with a complete neonatal follow-up up to 1 month after delivery.
Results: Seven cases of hypertensive complications were observed during pregnancies. No cases of congenital anomalies in neonates were observed.
Conclusion: Although many more cases are necessary to demonstrate that sibutramine is not teratogenic in pregnancy, our experience improves the counseling of pregnancies occurring involuntarily during sibutramine therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Astrup A, Hansen DL, Lundsgaard C, et al. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998 Aug; 22Suppl. 1: S30–5
Fanghanel G, Cortinas L, Sanchez-Reyes L, et al. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000; 24: 144–50
Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331–9
James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119–25
Meridia (sibutramine HCl monohydrate, anorexiant-antiobesity). In: Compendium of pharmaceuticals and specialities. Ottawa (ON): Canadian Pharmacists Association, 2002: 980–4
Yanovski SZ, Yanovski JA. Drug therapy: obesity. N Engl J Med 2002; 346: 591–602
US FDA. Meridia® label [online]. Available from URL: http://www.fda.gov/cder/foi/label NDA n° 20-632. [Accessed 2004 Jul 1]
Robert E, Francannet C, Shaw G. Neural tube defects and maternal weight reduction in early pregnancy [abstract]. Reprod Toxicol 1994; 8: 448
Robert E, Francannet C, Shaw G, Kallen B. Neural tube defects and maternal weight reduction in early pregnancy. Reprod Toxicol 1995 Jan-Feb; 9(1): 57–9
Einarson A, Bonari L, Sarkar M, et al. Exposure to sibutramine during pregnancy: a case series. Eur J Obstet Gynecol Reprod Biol 2004 Sep 10; 116(1): 112
Kadioglu M, Ulku C, Yaris F, et al. Sibutramine use in pregnancy: report of two cases. Birth Defects Res A Clin Mol Teratol 2004 Aug; 70(8): 545–6
Connoley IP, Liu YL, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999 Mar; 126(6): 1487–95
Advisory: Health Canada investigates safety of Meridia (sibutramine). Ottawa (ON): Health Canada, 2002 Mar 27 [online]. Available from URL: http://www.hc-sc.gc.ca/english/protection/warnings/2002/2002_21e.htm [Accessed 2004 Jul 1]
Woodman R. Abbott says no link between deaths, obesity drug. Reuters 2002 Mar 15, story ID 707119
Wolfe SM, Sasich LD, Barbenhenn E. Petition to FDA to ban the diet drug sibutramine (Meridia) [HRG publ no 1613]. Washington, DC: US Food and Drug Administration, 2002 Mar 19 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/dailys/02/Mar02/032202/02p-0120_cp00001_vol1.pdf [Accessed 2002 Apr 17]
Acknowledgements
The author did not receive funding for the preparation of this study and has no conflicts of interest directly related to the contents of the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Santis, M., Straface, G., Cavaliere, A.F. et al. Early First-Trimester Sibutramine Exposure. Drug-Safety 29, 255–259 (2006). https://doi.org/10.2165/00002018-200629030-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200629030-00008